cmsc16

#CMSC16 – Novel Model of Home Care for Patients with Progressive MS Proven Beneficial, Increased Patients’ Satisfaction

A new model of care implemented to address the needs of patients with progressive multiple sclerosis (MS) and their caregivers has provenĀ beneficial by reducing hospital stays, avoiding major care expenses, and improving patients’ satisfaction. The model has been tested in MS patients with high disability scores, and preliminary results of…

#CMSC16 – Interview with Bayer’s VP and General Manager on Betaconnect/Betaseron and Customized Therapy

Global pharmaĀ Bayer HealthcareĀ aims toĀ improve human health by diagnosing, preventing, and treating a variety of diseases. The company currently provides products for general medicine, hematology, neurology, oncology, and women’s healthcare. In 1993, Bayer’s BetaseronĀ (interferon beta-1b) became the first disease-modifying drugĀ to be approved by the U.S. Food and Drug Administration (FDA)Ā for…

#CMSC16 – Home Evaluation Prototype to Improve At-home Rehabilitation After Hospitalization

Researchers at the Shepherd Center in Atlanta areĀ developing a prototype that addresses physical and cognitive parameters, daily routines, and homes of patients to better implement rehabilitation within the home environment. The study wasĀ presented in “Functional Home Evaluation: Missing Pieces in Treatment and Transition Processes” during the Consortium…

#CMSC16 – Study of PPMS Patient Characteristics Highlights Need for More Information

PeopleĀ with primary progressive multiple sclerosis (PPMS)Ā are usually older and more disabled than thoseĀ withĀ relapsing-remitting MS, researchers atĀ Washington UniversityĀ reported. The team is studying demographic and clinical characteristics of PPMS patients enrolled in theĀ NARCOMSĀ registry, to better understand their unmet needs and possibly improve research into potential treatments. The study, ā€œ…

#CMSC16 – Visual Assessment May Provide Information on Cognitive Function in MS Patients

Researchers at Johns Hopkins University in Baltimore found that visual function in multiple sclerosis (MS) patients correlates with cognitive function ands suggests that disease severity and outcomes of neuroprotective therapies in MS patients may be assessed through visual function measurements. The findings were recently presentedĀ in the oral presentation “…

#CMSC16 – Treadmill Walking Improves Cognitive Processing in MS Patients

Treadmill walking exercise training is beneficial for multiple sclerosis (MS) patients, increasing not only their cardiorespiratory fitness, but also their cognitive processing speed, according to the study “Systematically Developed Pilot Randomized Controlled Trial of Exercise and Cognition in Persons with Multiple Sclerosis,” recently presented at theĀ Consortium of Multiple…

#CMSC16 – Robot-assisted Rehabilitation May Improve MS Patient Locomotor Function

Robot-assisted training may be anĀ effective therapy to improve motor function in the lower limbs of patients with multiple sclerosis (MS), and help in rehabilitation, according to the study “Robot-Guided Rehabilitation Improves Sensorimotor Functions in Lower-Limb Impairments of Individuals with Multiple Sclerosis,” presented at theĀ Consortium of Multiple Sclerosis Centers…

#CMSC16 – Medical Affairs VP at EMD Serono Discusses MS Drug Rebif, MS LifeLines Support in Exclusive Interview

EMD Serono,Ā the U.S. and Canadian subsidiary and biopharmaceutical business of Merck KGaA,Ā focuses exclusively on specialty care. With expertise inĀ fertility, endocrinology, oncology and neurology, the company is featuring several innovative products with therapeutic potential in the oncology, immuno-oncology, and immunology fields. Rebif (interferon beta-1a), EMD Serono’s therapyĀ for patients withĀ relapsing…

#CMSC16 – Lifestyle Factors and Unconventional Medicine in MS Care

A symposium focused on lifestyle factors and unconventional medicine as part of the clinical care provided to patients with multiple sclerosis (MS) took placeĀ today at theĀ 2016 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC). The symposium, “Expanding the MS Toolkit: Integrating Lifestyle Factors and Unconventional Medicine…

#CMSC16 – MS Expert Fred Lublin Discusses Relevance of MS Relapses

Dr. Fred Lublin,Ā a renowned multiple sclerosis (MS) expert atĀ Mount Sinai Medical Center, helped launch theĀ Consortium of Multiple Sclerosis Centers (CMSC) 2016 Annual Meeting,Ā June 1 – 4, in National Harbor, Md. with the John F. Kurtzke Memorial Lecture he titledĀ ā€œDo Relapses Really Matter?ā€ ā€œHow relapses influence disease worsening,…

#CMSC16 – Dr. Ellen Mowry, in Interview, Talks of Clinical Studies into Vitamin D and MS

With an interestĀ multiple sclerosisĀ (MS) beforeĀ even startingĀ college, Dr. Ellen Mowry has spent her entire research career investigatingĀ the disease. Her epidemiological studies led her to indications that vitamin D might be particularly important for peopleĀ with MS, and she now dedicates her research to the topic ā€” knowledge she will share at the…

#CMSC16 – MS Experts Agree on Benefits of Vitamin D Supplements, Despite Mostly Circumstantial Evidence

A roundtable discussion, provided as a webinarĀ organized by theĀ Consortium of Multiple Sclerosis Centers (CMSC)Ā in advance of its June conference, considered the role of vitamin D in multiple sclerosis (MS). Researchers concluded that, while evidence is only circumstantialĀ as to theĀ vitamin’s ability to prevent disease relapses, its multiple health benefits justify…

#CMSC16 – Dr. Fred Lublin to Deliver Opening Lecture on MS Relapses and Their Impact on Patient Outcomes

The Consortium of Multiple Sclerosis Centers (CMSC) 2016 Annual Meeting will open with the John F. Kurtzke Memorial Lecture,Ā ā€œDo Relapses Really Matter?ā€,Ā by the renowned multiple sclerosis (MS) expertĀ Dr. Fred D. Lublin of Mount Sinai Medical Center. The June 1 lectureĀ offers a fresh view on recent evidence intoĀ the impact…